Results 121 to 130 of about 12,023 (194)

Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022) [PDF]

Funding Information: Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. This research was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project ...
Bianco, Gabriele, Costa, Cristina, Bastos, Paulo, Almeida, André, Cavallo, Rossana, Boattini, Matteo, Comini, Sara, De Rosa, Francesco Giuseppe, Corcione, Silvia   +8 more
core   +1 more source

Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study

Infection and Drug Resistance
Yun Han,1,* Jianping Zhu,1,* Jieqiong Liu,2 Ying Zheng,2 Gang Liang,1 Yi Yang,1 Lingyan Yu,3 Zhenwei Yu,1 Gang Han1 1Research Center for Clinical Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, College of Pharmaceutical Sciences ...
Han Y, Zhu J, Liu J, Zheng Y, Liang G, Yang Y, Yu L, Yu Z, Han G   +8 more
doaj  

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Mithilesh Kumar Jha, Mukesh Kumar, Sunali, Maneesh Kumar, Nishant Ranjan   +4 more
core   +1 more source

ESBL termelő baktériumok ceftazidim/avibactam érzékenységének in vitro vizsgálata

, 2015
ESBL termelő törzsek érzékenységének ceftazidim/avibactam kombináció és különböző carbapenemek (imipenem, meropenem, doripenem) in vitro vizsgálata. A célkitűzésem az volt, hogy az in vitro eredmények alapján a ceftazidim/avibactam kombináció megfelelő ...
Incze, Boglárka
core  

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022). [PDF]

J Antimicrob Chemother
Yang Q, Tuon FF, Shah S, Kamat S, Mohamed N, Stone GG, Perez KK, Cantón R.   +7 more
europepmc   +1 more source

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant <i>Escherichia coli</i> using a hollow fiber infection model: a proof-of-concept study. [PDF]

Antimicrob Agents Chemother
Walker MM, Roberts JA, Li Y, Naicker S, Wallis SC, Ordonez JL, Won H, Forde BM, Sime FB.   +8 more
europepmc   +1 more source

Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. [PDF]

Emerg Infect Dis
Long T, Lovey A, Sanborn L, Zhao Y, Bulman ZP, Lin YT, Chen L.   +6 more
europepmc   +1 more source

Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-Producing <i>Klebsiella pneumoniae</i> CNS Infection: A Case Report. [PDF]

Infect Drug Resist
Qi G, Cong W, Zhang M, Wang S, Bai Z, Li B, Chen H.   +6 more
europepmc   +1 more source

<i>In vitro</i> activity of aztreonam-nacubactam and cefepime-nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021-2023. [PDF]

JAC Antimicrob Resist
Karlowsky JA, Estabrook M, Suzuki E, Shimizu A, Okade H.   +4 more
europepmc   +1 more source

Comparison of laboratory-developed methods for aztreonam plus ceftazidime-avibactam antimicrobial susceptibility testing for metallo-beta-lactamase-producing Enterobacterales. [PDF]

J Clin Microbiol
Bhatnagar AS, Harris H, Jacobs E, Bumpus-White P, Balbuena R, Stambaugh H, Crayton K, Haynie J, Quintero Ilutsik J, Longo C, Bergman Y, Singh S, Murray M, Sabour S, Robinson ML, Machado M-J, Simner PJ.   +16 more
europepmc   +1 more source